Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
GPR146 Biologics Sequence Review Report 2026: G protein-coupled receptor 146 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR146 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR142 Biologics Sequence Review Report 2026: G protein-coupled receptor 142 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR142 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR135 Biologics Sequence Review Report 2026: G protein-coupled receptor 135 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR135 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GPR119 Biologics Sequence Review Report 2026: Glucose-dependent insulinotropic receptor Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of GPR119 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FLT3LG Biologics Sequence Review Report 2026: Fms-related tyrosine kinase 3 ligand Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FLT3LG protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FGFBP3 Biologics Sequence Review Report 2026: Fibroblast growth factor-binding protein 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGFBP3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FGFBP2 Biologics Sequence Review Report 2026: Fibroblast growth factor-binding protein 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGFBP2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FGFBP1 Biologics Sequence Review Report 2026: Fibroblast growth factor-binding protein 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGFBP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FGF8 Biologics Sequence Review Report 2026: Fibroblast growth factor 8 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FGF23 Biologics Sequence Review Report 2026: Fibroblast growth factor 23 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF23 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FGF22 Biologics Sequence Review Report 2026: Fibroblast growth factor 22 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FGF20 Biologics Sequence Review Report 2026: Fibroblast growth factor 20 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.